Page 112 - Haematologica Vol. 107 - September 2022

ARTICLE - iLLUMINATE: final analysis
C. Moreno et al.
reduction in the risk of disease progression or death with ibrutinib plus obinutuzumab (hazard ratio [HR]=0.25; 95% CI: 0.16-0.39; P<0.0001) (Figure 1). The estimated PFS at 42 months was 74% in the ibrutinib plus obinu- tuzumab arm and 33% in the chlorambucil plus obinu- tuzumab arm.
Similar to the overall population, there was a significant
PFS benefit for patients with high-risk features (del[17p], del[17p]/TP53 mutation, del[11q] and/or unmutated IGHV) treated with ibrutinib plus obinutuzumab versus chloram- bucil plus obinutuzumab (HR=0.17; 95% CI: 0.10-0.28; P<0.0001). Within the high-risk population, PFS estimates at 42 months were significantly higher in the ibrutinib plus obinutuzumab arm than in the chlorambucil plus obinu-
Figure 1. Progression-free survival per investigator assessment in the intention-to-treat population. CI: confidence interval; mo: months; NE, not estimable; PFS, progression-free survival.
Figure 2. Progression-free survival per investigator assessment in the high-risk population of patients with del(17p), del(11q), TP53 mutations, and/or unmutated IGHV. CI: confidence interval; mo: months; NE: not estimable; PFS: progression-free survival.
Haematologica | 107 September 2022
2111